Procedure utilizing CorPath System highlights precision stenting for ACC14 attendees
Waltham, MA – April 30, 2014 – Detroit Medical Center Harper Hospital presented a live CorPath robotic assisted percutaneous coronary intervention (PCI), or coronary angioplasty, during the American College of Cardiology (ACC) annual meeting on March 29. The procedure, which was transmitted live to Washington, D.C. for the 13,000 meeting attendees, was led by Dr. Ted Schreiber, President of the Cardiovascular Institute and Director of the Cardio OneTM Team at DMC Harper Hospital. Dr. Schreiber was the driving force behind the launch of the CorPath robotic angioplasty program at DMC, the first robotic angioplasty program in the Midwest.
Dr. Amir Kaki, medical director of cardiac catheterization laboratories at Detroit Medical Center, performed the procedure using the CorPath System, the first FDA-cleared device to bring robotic precision to coronary angioplasty, helping to optimize clinical outcomes. During the case, Dr. Kaki was able to control the advancement and placement of the balloon/stent catheter with enhanced precision from within the CorPath’s interventional cockpit. The accuracy provided by the system’s measurement function enabled Dr. Kaki to identify the most appropriate length stent for the patient. During the case, Dr. Kaki precisely placed the stent using the millimeter-by-millimeter movement while the audience watched from the conference hall.
Dr. Kaki performed the angioplasty on a high-grade, complex, ulcerated lesion that was blocking 90 percent of the blood flow through a major artery in the heart. Navigating the wire and placing the stent in lesions like this can be difficult, but using the CorPath system, the case went very smoothly.
“The improvements in precision and accuracy provided by robotic-assisted systems enable a higher level of precision for interventional cardiologists, which then gives them significant confidence in reassuring patients they are receiving the best possible care,” said Dr. Kaki. “Knowing the exact measurement of the relevant anatomy–down to the sub-millimeter – can positively impactpatient outcomes in coronary angioplasty procedures.”
Dr. Schreiber said, “We are proud to be able to show a case live from DMC Harper Hospital that offers the interventional cardiology community a glimpse behind the technology that is transforming the way safety and precision are defined in PCI procedures.”
The CorPath System is the first and only FDA-approved technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. During a CorPath procedure, the interventional cardiologist sits in the radiation shielded interventional cockpit and advances stents and guidewires using digital controls with millimeter-by-millimeter robotic precision. CorPath may improve clinical outcomes by enabling precise measurement of the anatomy, which could potentially lead to better stent placements.
“The precision enabled by robotics in coronary angioplasty procedures may deliver benefits to the entire care cycle. Patients benefit from potentially optimized clinical outcomes, physicians benefit from significantly reduced radiation exposure and facilities can benefit from minimizing costs of additional stent placements and follow-up procedures,” said David Handler, President and CEO of Corindus Vascular Robotics. “We will continue to work with Dr. Schreiber, Dr. Kaki and other leaders in interventional cardiology to showcase the safety standards and care quality achievable in PCI procedures through vascular robotics.”
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements: